• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-NPC2

NPC2 Polyclonal Antibody for WB, IHC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 19888-1-PBS

Synonymes



Informations sur le produit

19888-1-PBS cible NPC2 dans les applications de WB, IHC, Indirect ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène NPC2 Protéine recombinante Ag13719
Nom complet Niemann-Pick disease, type C2
Masse moléculaire calculée 151 aa, 17 kDa
Poids moléculaire observé17-21 kDa
Numéro d’acquisition GenBankBC002532
Symbole du gène NPC2
Identification du gène (NCBI) 10577
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Niemann-Pick Type C (NPC) disease is a lysosomal storage disorder characterized by accumulation of unesterified cholesterol and other lipids in the endolysosomal system. NPC disease results from a defect in either of two distinct cholesterol-binding proteins: a transmembrane protein, NPC1, and a small soluble protein, NPC2. NPC1 or NPC2 deficiency models showed that the function of these two proteins within lysosomes are linked closely. NPC2 is also named human epididymis-specific protein 1 (HE1), defects of which are the cause of Niemann-Pick disease type C2, characterized as a lysosomal storage disorder that affects the viscera and the central nervous system. Recent finding suggests that NPC2 may serve as a novel intracrine/autocrine factor that controls adipocyte differentiation and function as well as potential therapeutic target for the treatment of type 2 diabetes and related metabolic disorders.

{{ptg:RelatedPrimaryAntibodies}}